الفهرس 
”Phase III Randomized Study of Adjuvant Whole Breast Versus Partial Breast Irradiation in Women With Ductal Carcinoma In Situ or Stage I or II Breast Cancer
Table of contentsOnly 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
This is a phase III randomized trial comparing whole breast irradiation (WBI) vs. accelerated partial breast irradiation (APBI) for patients with stage I and II breast cancer treated with breast conserving surgery. Between January 2012 and October 2013, 60 patients were enrolled onto this study, 30 patients in each treatment arm. Patients in the APBI group received 3850 cGy/10F given twice daily with a minimum of 6 hours apart, while patients in the WBI group received 5000 cGy/25F in 5 weeks with an additional 10Gy/5F boost to the tumor bed. The aim of this study was to compare local tumor control, overall survival, toxicity (acute and late), and cosmesis in women treated with either APBI or WBI. The median age of patients was 47 years (52 in the WBI arm and 46 in the APBI arm). The mean tumor size was 1.96 cm (1.8 in the APBI and 2.1 in the WBI arm). Five (16.6%) patients in the APBI arm had metastatic axillary lymph nodes while 4 patients (13.4%) had node positive disease in the WBI arm. At a median follow up of 17.4 months, none of the patients experienced local, regional or distant recurrences. All patients were alive at the time of last follow up. When compared to WBI, APBI resulted in lower dose received by the ipsilateral lung. The mean V10 was 10.2% vs. 31.4%, p 0.02 and mean V20 was 3.83% vs. 23.07%, p 0.001, for APBI and WBI respectively